Form D · Biotechnology
NAT Diagnostics, Inc.
San Diego, CA · CIK 0001640306
Offering snapshot reported Nov 16, 2017 · SEC filing
- Reported sold
- $1.5M Offering amount: $1.5M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $12.2K Reported outside-investor minimum
- First sale
- Nov 15, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2017 | Initial | $1,500,000 | No comparison | 18 | SEC filing |
| Sep 11, 2015 | Amendment | $2,910,007 | $1,610,007vs Apr 22, 2015 | 18 | SEC filing |
| Apr 22, 2015 | Initial | $1,300,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-298932
Source: Form D, filed Nov 16, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Allan Fan | Director |
| David J. Galas | Director |
| Andrew P. Miller | Director, Executive |
| Thomas Wu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11585 Sorrento Valley Rd., Ste. 107
San Diego, CA, 92121
San Diego, CA, 92121